Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) FCF Margin (2021 - 2025)

Krystal Biotech (KRYS) has disclosed FCF Margin for 4 consecutive years, with 70.1% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 1766.0% to 70.1% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 50.84% through Dec 2025, up 1128.0% year-over-year, with the annual reading at 50.83% for FY2025, 1128.0% up from the prior year.
  • FCF Margin hit 70.1% in Q4 2025 for Krystal Biotech, up from 48.2% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 822.32% in Q1 2021 to a low of 249.31% in Q3 2023.
  • Historically, FCF Margin has averaged 81.83% across 4 years, with a median of 47.94% in 2025.
  • Biggest five-year swings in FCF Margin: skyrocketed 31830bps in 2024 and later plummeted -2078bps in 2025.
  • Year by year, FCF Margin stood at 822.32% in 2021, then tumbled by -102bps to 18.81% in 2023, then skyrocketed by 379bps to 52.44% in 2024, then soared by 34bps to 70.1% in 2025.
  • Business Quant data shows FCF Margin for KRYS at 70.1% in Q4 2025, 48.2% in Q3 2025, and 47.94% in Q2 2025.